Market Opportunity: MyHealthTrends for Pain

MyHealthTrends for Pain will be sold into distinct markets, including the Hospital and Healthcare markets; the Consumer market; and in support of pharmaceutical company marketing and development activities.

Hospital and Healthcare Market

If pain is to be monitored in one hospital patient, it must be monitored in all hospital patients. Therefore, the market for the pain monitoring system consists of all:

7,000 JCAHO accredited hospitals in the United States
5,000 Freestanding patient care facilities
17,000 Nursing homes
Multiple healthcare institutions abroad

Based upon 303.4 million individuals currently within the United States and a hospital admission rate at 80/1000 (8.0%), there are approximately 24.2 million hospital admissions per year in the U.S. alone. Ultimately, each patient should become a recipient of a pain monitoring device - defining the institutional market size.

Consumer Market

The consumer market consists of individuals who are impacted with any chronic or acute pain affliction. Therefore, the market for MyHealthTrends for Pain also consists of all non-hospital patients concerned with pain management. This includes patients of cancer and those with back pain, postoperative pain, neuropathic pain, osteoarthritis, fibromyalgia, and refractory migraine.

Pharmaceutical Companies

Given MyHealthTrends for Pain is a precise tool for identification of breakthrough pain episodes, it is also an ideal marketing tool for pharmaceutical companies that compete in $2 billion Breakthrough Pain Market. Future customers include:

Cephalon (Actiq®, annual sales of $500 MM)
BioDelivery Sciences International (BEMA™ Fentanyl, peak annual sales of $250 MM)
EndoPharmaceuticals (Rapinyl™, NDA to be filed 2008)
Abbott Labs (Dilaudid, annual sales of $65 MM)